MedinCell (MEDCL) Stock Overview
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MEDCL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
MedinCell S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.58 |
| 52 Week High | €27.26 |
| 52 Week Low | €12.00 |
| Beta | 1.16 |
| 1 Month Change | 55.44% |
| 3 Month Change | 57.84% |
| 1 Year Change | 74.18% |
| 3 Year Change | 380.65% |
| 5 Year Change | 294.36% |
| Change since IPO | 261.63% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Recent updates
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
Sep 25Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
Jun 19Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
Dec 25MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Shareholder Returns
| MEDCL | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 18.7% | 9.9% | 3.0% |
| 1Y | 74.2% | -13.4% | 5.4% |
Return vs Industry: MEDCL exceeded the French Pharmaceuticals industry which returned -13.8% over the past year.
Return vs Market: MEDCL exceeded the French Market which returned 5.8% over the past year.
Price Volatility
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: MEDCL has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: MEDCL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 131 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
| MEDCL fundamental statistics | |
|---|---|
| Market cap | €879.64m |
| Earnings (TTM) | -€18.44m |
| Revenue (TTM) | €27.73m |
Is MEDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDCL income statement (TTM) | |
|---|---|
| Revenue | €27.73m |
| Cost of Revenue | €0 |
| Gross Profit | €27.73m |
| Other Expenses | €46.17m |
| Earnings | -€18.44m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Dec 09, 2025
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -66.50% |
| Debt/Equity Ratio | -394.7% |
How did MEDCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 16:18 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedinCell S.A. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Brian Balchin | Jefferies LLC |